Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lushang Freda Pharmaceutical Co.,Ltd. (600223.SS)
Jinan, CN
Lushang Freda Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of cosmetics, pharmaceuticals, raw materials, and additives in China. It is involved in property management services. The company provides facial cleansers, lotions, creams, sprays, masks, and other products. It also offers products in the field of dermatology, orthopedics, ophthalmology, gynecology, and pediatrics, respiratory, endocrinology, andrology, tonic, and plasters, as well as hyaluronic acid and its derivatives, bio-fermentation, plant extracts, chemical synthesis, tablets, capsules, drinks, injections, granules, and other products. The company offers its products through online and offline channels. It exports its products to North America, the European Union, Japan, South Korea, and Southeast Asia. The company was formerly known as Lushang Health Industry Development Co.,Ltd. and changed its name to Lushang Freda Pharmaceutical Co.,Ltd. in April 2023. The company was founded in 1993 and is based in Jinan, China. Lushang Freda Pharmaceutical Co.,Ltd. is a subsidiary of Shandong Commercial Group Co.,Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.68% | -2.89% | -7.63% | -18.02% | -20.92% | -17.80% | -22.54% | -41.09% | -67.19% | +24.49% | -15.15% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-9.0% Q1'26: +2.8% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-25.0% Q1'26: -40.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+2.2% Q1'26: -5.1% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.8% Q1'26: +4.9% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+6.5% ★ Q1'26: +6.7% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.2% Q1'26: +4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.50× ★ Q1'26: 0.96× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.86B
est: 6.05B (-3.1%)
|
7.65B
est: 7.65B (0.0%)
|
8.29B
est: 9.56B (-13.3%)
|
8.82B
est: 12.52B (-29.5%)
|
10.29B
est: 11.47B (-10.3%)
|
13.62B
est: 10.71B (+27.1%)
|
12.36B
est: 13.84B (-10.7%)
|
12.95B
est: 12.52B (+3.4%)
|
4.58B
est: 4.03B (+13.6%)
|
3.98B
est: 4.16B (-4.3%)
|
3.63B
est: 3.90B (-7.0%)
|
3.94B
3.82B – 4.06B
+1.2% YoY
|
4.29B
4.06B – 4.53B
+8.8% YoY
|
4.63B
4.62B – 4.64B
+7.9% YoY
|
| EBITDA |
306.55M
est: 401.54M (-23.7%)
|
262.93M
est: 507.47M (-48.2%)
|
414.18M
est: 634.30M (-34.7%)
|
550.16M
est: 830.96M (-33.8%)
|
498.75M
est: 761.11M (-34.5%)
|
851.95M
est: 710.77M (+19.9%)
|
729.53M
est: 918.40M (-20.6%)
|
692.15M
est: 831.07M (-16.7%)
|
363.55M
est: 282.60M (+28.6%)
|
308.37M
est: 291.85M (+5.7%)
|
294.63M
est: 273.31M (+7.8%)
|
276.47M
268.13M – 284.44M
+1.2% YoY
|
300.94M
284.80M – 317.29M
+8.8% YoY
|
324.67M
324.11M – 325.22M
+7.9% YoY
|
| EBIT |
277.28M
est: 309.60M (-10.4%)
|
231.96M
est: 391.27M (-40.7%)
|
347.43M
est: 489.06M (-29.0%)
|
483.27M
est: 640.69M (-24.6%)
|
434.53M
est: 586.84M (-26.0%)
|
765.96M
est: 548.02M (+39.8%)
|
636.91M
est: 708.11M (-10.1%)
|
575.66M
est: 640.77M (-10.2%)
|
227.71M
est: 199.32M (+14.2%)
|
214.71M
est: 205.85M (+4.3%)
|
172.71M
est: 192.77M (-10.4%)
|
195.00M
189.12M – 200.62M
+1.2% YoY
|
212.26M
200.87M – 223.79M
+8.8% YoY
|
228.99M
228.60M – 229.38M
+7.9% YoY
|
| Net Income |
112.49M
est: 226.28M (-50.3%)
|
92.37M
est: 91.32M (+1.1%)
|
128.07M
est: 118.72M (+7.9%)
|
162.06M
est: 175.54M (-7.7%)
|
344.51M
est: 294.26M (+17.1%)
|
638.67M
est: 527.64M (+21.0%)
|
361.90M
est: 769.47M (-53.0%)
|
45.46M
est: 69.34M (-34.4%)
|
303.39M
est: 240.21M (+26.3%)
|
243.53M
est: 271.37M (-10.3%)
|
187.75M
est: 251.56M (-25.4%)
|
243.30M
218.74M – 260.40M
-3.3% YoY
|
292.45M
243.98M – 355.80M
+20.2% YoY
|
345.21M
259.12M – 445.70M
+18.0% YoY
|
| SGA |
317.51M
est: 1.36B (-76.6%)
|
320.69M
est: 1.71B (-81.3%)
|
734.57M
est: 2.14B (-65.7%)
|
821.63M
est: 2.80B (-70.7%)
|
1.02B
est: 2.57B (-60.2%)
|
1.16B
est: 2.40B (-51.8%)
|
1.62B
est: 3.10B (-47.7%)
|
1.65B
est: 2.81B (-41.1%)
|
1.67B
est: 1.17B (+42.1%)
|
1.64B
est: 1.21B (+35.7%)
|
1.52B
est: 1.13B (+34.0%)
|
1.15B
1.11B – 1.18B
+1.2% YoY
|
1.25B
1.18B – 1.32B
+8.8% YoY
|
1.35B
1.34B – 1.35B
+7.9% YoY
|
| EPS |
0.11
est: 0.22 (-50.7%)
|
0.09
est: 0.09 (+0.0%)
|
0.13
est: 0.12 (+11.1%)
|
0.16
est: 0.17 (-6.4%)
|
0.34
est: 0.29 (+18.7%)
|
0.63
est: 0.52 (+21.2%)
|
0.36
est: 0.76 (-52.5%)
|
0.04
est: 0.07 (-34.6%)
|
0.30
est: 0.24 (+24.8%)
|
0.24
est: 0.27 (-10.1%)
|
0.18
est: 0.25 (-27.3%)
|
0.24
0.22 – 0.26
-2.0% YoY
|
0.29
0.24 – 0.35
+19.6% YoY
|
0.35
0.25 – 0.44
+19.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 232.1K | 0.06% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 93.2K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 76.6K | 0.29% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 16.1K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.1K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 793.0K | 0.06% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 36.7K | 0.28% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 12.0K | 0.10% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 852.6K | 0.05% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.3K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ai Min Yang | Accounting Supervisor | — | — |
| Baiqiang Xu | Financial Director | — | male |
| Chunming Gao | Deputy General Manager | — | male |
| Deqiang Zheng | Deputy General Manager | — | male |
| Hongyang Zhang | Deputy GM & Secretary | — | male |
| Xixi Dou | Deputy General Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600223.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
